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Health-related quality of life predicts outcomes but is not af-
fected by peritoneal clearance: The ADEMEX trial.
Background. We hypothesized that increasing small solute
clearance in peritoneal dialysis (PD) would lead to improve-
ments in patient health-related quality of life (HRQOL).
Methods. Patients were randomized to a control group [stan-
dard 4×2L continuous ambulatory peritoneal dialysis (CAPD)]
and an intervention group (CAPD with a target creatinine clear-
ance ≥60L/week/1.73m2). The Kidney Disease Quality of Life
Short Form was obtained at baseline and at 6, 12, and 24 months.
Physical (PCS), mental (MCS), and kidney disease component
summary (KDCS) scores were computed.
Results. The two groups were comparable at baseline with re-
spect to HRQOL. Baseline variables highly predictive of better
QOL included absence of diabetes, younger age, higher starting
GFR, and serum albumin. Baseline values of QOL were highly
predictive of survival and hospitalizations.
An unadjusted comparison revealed that patients in the inter-
vention group had significantly higher PCS and KDCS scores at
six months. However, there were no significant differences be-
tween the intervention and control patients at 12 or 24 months.
When similar analyses were carried out adjusting for different
patterns of patient dropout, there were no significant differ-
ences between the two groups at any time point in terms of
PCS, MCS, and KDCS scores.
Conclusion. We found no evidence of a long-term benefit
in HRQOL of CAPD patients by increasing peritoneal small-
solute clearances when HRQOL parameters were adjusted for
patient dropout. Measures of HRQOL have a significant pre-
dictive value for patient survival and hospitalizations.
Patients’ perception of their well-being and patient-
reported outcomes are becoming an integral part of cur-
rent evaluations of the human cost of chronic illnesses
and the assessment of the impact of therapeutic inter-
ventions [1–8]. These trends have been reflected in the
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field of renal replacement therapies (RRT) by the string
of publications, both cross-sectional [7, 9–24] and longi-
tudinal [3, 4, 12, 25, 26], examining the determinants of
health-related quality of life (HRQOL) in patients with
end-stage renal disease (ESRD) and the predictive value
of findings using a variety of evaluative instruments [15,
23, 26–28]. Indeed, measures of HRQOL have not only
become popular investigative tools, but have been used in
an effort to define and alter models of healthcare delivery
[2, 29, 30].
In patients on hemodialysis (HD), several factors have
been identified to influence HRQOL, including gender
[13, 14], race [9, 10, 19, 24, 31], socioeconomic status
[10, 20, 26, 32], body mass index [16], comorbidity [9,
10, 14, 20, 32–36], nutritional status [14, 16, 20, 32], ane-
mia [14, 16, 34, 35], and evidence of inflammation [16]. In
HD patients, dialysis dose has not been found to affect
HRQOL measures [14, 16, 20, 32], while contradictory
findings have been reported for age [16, 20, 32, 34, 35]
and duration of dialysis [14, 16]. Further, in patients on
HD, measures of HRQOL have been found to be strong
independent predictors of hospitalization and increased
risk of death [16, 23, 24, 37], but not of compliance with di-
alytic therapy [38]. HRQOL in patients on HD has been
observed to decline over time [34].
Determinants of HRQOL have been less studied in
patients on peritoneal dialysis (PD), and all studies to
date were in small patient groups. Nevertheless, in PD
patients, the following factors have been identified to in-
fluence HRQOL measures: gender [25], race [25], socioe-
conomic status [25], body mass index [25], comorbidity
[25, 34, 35], anemia [1], nutritional status [25, 35], and
residual renal function [34, 35]. In PD patients, dialysis
dose has not been found to affect HRQOL measures [25,
34, 39], nor have indices of inflammation [25]. Further, in
patients on PD, measures of HRQOL have been found to
be strong independent predictors of hospitalization and
increased risk of death [25, 37]. HRQOL in patients on
PD, like in patients on HD, has been observed to decline
over time [25, 34].
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To date, there have been very few large-scale studies
that have investigated the determinants of HRQOL in
patients on PD or the impact of prospective increments
in small solute clearances on various patient outcomes, in-
cluding HRQOL. While a number of smaller-scale stud-
ies have examined the association between small solute
clearance and patient HRQOL, these studies were obser-
vational in nature and studied small patient groups [25,
34, 39].
While most studies have failed to show a survival ben-
efit of increasing peritoneal small solute clearances be-
yond a range currently practiced [40–45], it has been
speculated that increasing peritoneal clearances may im-
prove other important outcome measures, such as patient
HRQOL. A randomized, prospective, controlled clinical
trial is required to substantiate the presence or absence of
a potential HRQOL effect from a high peritoneal clear-
ance. In this paper, we summarize results from the ADE-
MEX trial, a large-scale randomized, controlled trial de-
signed specifically to investigate the effects of increasing
peritoneal small solute clearance on various patient out-
comes, including quality of life [45].
METHODS
Patients and clinical trial design
We conducted a prospective randomized controlled
clinical trial called ADEMEX (ADEquacy of peritoneal
dialysis in MEXico), which examined the effect of in-
creasing peritoneal dialysis small solute clearances on se-
lect patient outcomes in individuals with ESRD treated
with continuous ambulatory peritoneal dialysis (CAPD).
The local clinical research committees of all participat-
ing centers approved the study protocol, and all study
subjects gave written informed consent. Patients were
recruited from 24 dialysis centers in 14 Mexican cities.
The study enrolled 965 patients on CAPD between June
1998 and May 1999. Patients were randomized into either
a control group (N = 484 patients receiving a standard
dose of 4×2L CAPD) or an intervention group (N = 481
patients receiving a modified CAPD prescription aimed
at achieving a creatinine clearance ≥60L/week/1.73m2).
By design, the study was terminated in May 2001, when
the last enrolled patient completed two years of follow-
up. A complete description of the study design, patient
characteristics, and more can be found in a previous pub-
lication [45].
KDQOL questionnaire
While the primary purpose of the study was to com-
pare patient survival between standard and high-dose
peritoneal dialysis, it was also hypothesized that an in-
crease in peritoneal small solute clearance may lead to
improved patient quality of life. To that end, quality of
life was assessed at baseline, and approximately at 6, 12,
and 24 months thereafter (a window of ± 2 months) us-
ing the Kidney Disease Quality of Life (KDQOL) ques-
tionnaire, short form, version 1.3 (KDQOL-SFTM), from
the Rand Corporation [46] which has been validated in a
Mexican population [47]. The KDQOL questionnaire is
a validated quality-of-life instrument that combines the
generic SF-36 instrument with a kidney disease-specific
instrument. The SF-36 instrument measures eight dimen-
sions or domains of functioning and well-being on a 100-
point scale (the higher the scale the better the patient’s
HRQOL). The eight domains are: (1) physical function-
ing; (2) role limitations caused by physical problems; (3)
pain; (4) general health; (5) energy/fatigue; (6) emotional
well-being; (7) role limitations caused by emotional prob-
lems; and (8) social function. In addition to individual
comparisons across all eight SF-36 domains, results from
the SF-36 instrument were further summarized into a
physical composite summary (PCS) score and a mental
composite summary (MCS) score using the RAND scor-
ing algorithm [46]. The PCS aggregates items from physi-
cal functioning, role-physical, bodily pain, general health,
vitality, and social functioning. The MCS aggregates items
from role-emotional, mental health, and also includes el-
ements of general health, vitality, and social functioning.
In the general population, the mean for each summary
scale is 50 points, with a standard deviation of 10 points.
The disease-specific component of the KDQOL instru-
ment measures eleven domains, also on a 100-point scale,
related to kidney disease [26]. These domains are: (1) bur-
den of kidney disease; (2) cognitive function; (3) dialysis
staff encouragement; (4) effects of kidney disease; (5) pa-
tient satisfaction; (6) quality of social interaction; (7) sex-
ual function; (8) sleep; (9) social support; (10) symptom
problem; and (11) work status. A kidney disease com-
ponent summary (KDCS) score, also on 100-point scale,
was computed per Mapes et al [23].
The KDQOL was administered to patients at visits
scheduled at approximately 6, 12, and 24 months fol-
lowing randomization. At each scheduled visit, patients
were asked to fill out the KDQOL questionnaire with all
patients, both literate and illiterate, assisted by a nurse
participating in the study. Studies in other dialysis popu-
lations have shown that interviewer-administered or as-
sisted surveys avoid selection bias [48].
Statistical methods
Pearson’s chi-square test and Fisher exact test were
used to compare discrete baseline patient characteristics
(e.g., gender, diabetes, comorbidity), while the Student
t test and Wilcoxon rank-sum test were used to com-
pare continuous variables at baseline (e.g., age, serum
chemistries, etc.). Life table techniques in combination
with a log-rank test, as well as Cox proportional hazards
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regression, were used to compare patient and technique
survival [49, 50]. Poisson regression with overdispersion
was used to compare hospital admission rates and hospi-
talization days.
Preliminary comparisons in the mean HRQOL scores
between control and intervention groups were carried
out using least squares analysis of variance (ANOVA) in
conjunction with robust generalized estimating equations
(GEE) for repeated measurements [51, 52]. Under this
initial analysis, unadjusted mean scores at each period of
follow-up were compared based on an ANOVA assuming
independent observations with homogeneous variances.
The ANOVA assumption of equal variances was evalu-
ated, and found to hold for both the composite scores
and individual HRQOL scores. Since repeated HRQOL
measurements within individuals tend to be correlated,
comparisons of the unadjusted means were carried out
using robust standard errors computed under the GEE
approach [51, 52].
In order for the unadjusted ANOVA to provide a
valid comparison of HRQOL between control and in-
tervention patients, the assumption is made that missing
data resulting from patient dropout or withdrawal prior
to completion of the study (e.g., dropout due to death,
change in therapy, transplant, etc.) is missing completely
at random (MCAR). This occurs when the probability of
dropout (i.e., withdrawal) from the study is independent
of both observed and unobserved values of the outcome
of interest, namely, HRQOL. In most studies of HRQOL,
this assumption is seldom met [53]. To safeguard against
violations to this assumption, a pattern-mixture repeated
measures analysis of covariance (ANCOVA) was carried
out in which HRQOL scores were compared between
control and intervention patients adjusting for different
patterns of patient dropout [54, 55]. There are four pat-
terns of missing data resulting from patient drop out. They
are: HRQOL measured at baseline followed by dropout
prior to month 6; HRQOL measured at baseline and
month 6 prior to dropout; HRQOL measured at base-
line, month 6, and month 12 prior to dropout; HRQOL
measured at baseline, month 6, month 12, and month 24
(patient completed the study).
A pattern-mixture repeated measures ANCOVA was
carried in which these four groups (i.e., dropout pat-
terns) were included as indicator covariates in an over-
all ANCOVA model in order that unbiased estimates of
mean HRQOL scores can be calculated and compared
between control and intervention patients [54, 55]. Av-
erage HRQOL scores were calculated as least squares
means averaged across the different patterns of missing
data using centered covariates [55]. Correlations were
accounted for by assuming a compound symmetric co-
variance structure. To protect against misspecification of
the covariance structure, all comparisons were carried out
using robust standard errors [51, 52]. Finally, preliminary
analyses revealed a low correlation between serum albu-
min and nPNA (correlation = 0.18), indicating that these
two variables could be included as joint covariates in the
various models without jeopardizing the interpretation
of results due to statistical multicollinearity.
RESULTS
Patient characteristics and baseline HRQOL findings
Of the 965 patients who participated in the ADE-
MEX trial, 923 had quality-of-life measurements at base-
line (460 control, 463 intervention), and are the subject
of this report and all subsequent results and analysis
contained herein. Patients in the two groups were sim-
ilar at baseline with respect to various demographic
measurements, ESRD etiology, dialysis parameters at
baseline, select serum chemistries, and quality-of-life
component summary scores (Tables 1 and 2). Similarly,
there were no differences between the control and inter-
vention groups with respect to baseline comorbid con-
ditions (data not shown). By study design, patients in
the intervention group had significantly greater peri-
toneal clearances compared to those in the control group.
Specifically, over the course of the study, mean peritoneal
creatinine clearances (mean ± 1 standard error) aver-
aged 46 ± .45 L/week/1.73m2 for the control group and
57 ± .48 L/week/1.73m2 for the intervention group (P <
0.001). Likewise, the mean peritoneal Kt/V values av-
eraged 1.62 ± 0.02 for control patients and 2.13 ± 0.02
for intervention patients (P < 0.001). There was no sig-
nificant difference in the time averaged GFR between
the two groups (intervention-control mean difference of
−0.20±0.11 mL/min, P =NS), nor were there differences
in nPNA and serum albumin values over the course of the
study.
Impact of enhanced clearance on HRQOL
Unadjusted mean HRQOL scores at baseline (time =
0) and at 6, 12, and 24 months thereafter are summarized
in Table 2. There is some evidence of an early benefit
in HRQOL at 6 months for patients in the intervention
group. Specifically, of the 19 HRQOL domains (11 KD
domains and eight SF-36 domains), a significant differ-
ence favoring the intervention group at six months was
observed in four of the domains (burden of kidney dis-
ease, effects of kidney disease, sexual function, and symp-
tom problem), while patients in the control group had a
significantly higher HRQOL score at six months in two
of the domains (cognitive function and quality of social
interaction) (Table 2). There were no statistically signif-
icant differences in mean HRQOL scores for any of the
eight SF-36 domains at any point during the study, al-
though there was evidence of moderate improvement in
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Table 1. Characteristics of the total study population at baseline and the two subgroups at randomization
Total Control Intervention
Factor N Mean/% SD N Mean/% SD N Mean/% SD
Demographics
Age 923 47.09 13.86 460 47.54 14.07 463 46.65 13.64
BSA 923 1.69 0.19 460 1.68 0.18 463 1.70 0.19
Female 390 42.25% 186 40.43% 204 44.06%
Male 533 57.74% 274 59.56% 259 55.93%
DM 392 42.47% 197 42.82% 195 42.11%
ESRD etiology
Diabetes 379 41.06% 191 41.52% 188 40.60%
Glomerulonephritis 57 6.17% 28 6.08% 29 6.26%
Hypertension 101 10.94% 52 11.30% 49 10.58%
Obstructive uropathy 24 2.60% 15 3.26% 9 1.94%
Other/unknown 320 34.66% 155 33.69% 165 35.63%
Dialysis parameters
Incident patients 388 42.03% 187 40.65% 201 43.41%
Prevalent patients 535 57.96% 273 59.34% 262 56.58%
Prior time on dialysis months 866 13.83 24.99 430 14.58 26.15 436 13.08 23.80
GFR mL/min 919 1.58 2.17 457 1.61 2.30 462 1.55 2.03
Basal GFR <1 mL/min 506 55.05% 259 56.67% 247 53.46%
Basal GFR >1 mL/min 413 44.95% 198 43.32% 215 46.53%
Peritoneal CrCl L/wk/1.73 923 44.61 8.71 460 44.70 8.98 463 44.51 8.44
Peritoneal Kt/V 910 1.59 0.38 452 1.58 0.37 458 1.59 0.39
Laboratory parameters
Serum creatinine mg/dL 923 10.75 3.80 460 10.80 4.02 463 10.69 3.57
Serum urea nitrogen mg/dL 910 52.51 17.53 452 52.79 17.80 458 52.24 17.27
Hematocrit% 764 28.56 5.98 382 28.85 6.16 382 28.27 5.80
Hemoglobin g/dL 864 9.08 1.92 431 9.19 1.96 433 8.97 1.89
Serum albumin g/dL 898 2.92 0.64 441 2.89 0.64 457 2.94 0.63
nPNA g/kg/day 901 0.80 0.22 445 0.81 0.23 456 0.80 0.21
Abbreviations are: DM, diabetes mellitus; nPNA, normalized protein nitrogen appearance rate. The control and intervention groups were identical for all measures.
Table 2. Baseline and follow up HRQOL measures in the two subgroups at randomization
Treatment
Control follow-up months Intervention follow-up months
0 6 12 24 0 6 12 24
Instrument Domain Mean Mean Mean Mean Mean Mean Mean Mean
N 460 342 269 117 463 212 153 72
KD QOL Kidney Disease Component Summary 53.4 53.1a 53.7 53.6 53.9 54.9 54.0 54.8
Symptom problem 76.2 77.8b 79.0 78.5 76.8 81.2 79.4 79.2
Dialysis staff encouragement 95.5a 95.7 96.2 97.3 97.3 96.7 97.4 94.5
Patient satisfaction 24.5 24.2 24.1 24.9 25.0 25.0 24.7 24.6
Effects of kidney disease 65.2 64.9b 67.3 66.9 65.7 69.4 66.7 69.0
Burden of kidney disease 41.8 44.2a 47.3 45.0 43.1 50.2 51.4 52.7
Work status 34.7 32.3 32.5 33.0 32.0 33.3 35.3 40.8
Cognitive function 28.6 27.1b 25.0 26.7 27.8 22.1 22.0 23.2
Quality of social interaction 24.5 24.3b 22.4 24.7 22.5 19.1 20.4 21.7
Sexual function 56.2 50.5b 57.7 46.4 61.3 67.7 50.6 63.0
Sleep 64.3 65.0 66.1 63.7 65.0 67.6 66.7 67.9
Social support 76.3 76.3 74.3 75.4 76.6 78.6 76.9 71.2
SF-36 Mental Component Summary 48.3 50.0 49.2 47.3 48.9 50.1 50.5 50.5
Physical Component Summary 37.3 36.8a 38.3 38.1 37.7 38.8 37.8 37.6
Physical functioning 52.2 50.6 51.0 52.7 54.0 53.5 52.6 52.8
Role-physical 38.8 43.6 46.3 42.9 39.4 46.1 43.8 46.5
Pain 68.8 68.8 72.9 70.3 69.3 73.3 72.6 67.7
General health 47.2 47.5 48.2 47.2 49.2 51.6 50.1 50.7
Emotional well-being 67.1 69.0 67.2 66.6 68.4 69.8 69.8 70.9
Role-emotional 63.5 70.3 68.5 60.7 65.4 68.4 72.0 70.0
Social function 67.9 70.4 70.5 70.4 68.5 72.6 72.8 69.9
Energy/fatigue 53.2 54.2 54.5 50.6 54.9 57.0 54.3 57.5
aP < 0.05 vs. intervention.
bP < 0.01 vs. intervention
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the physical component summary score at six months for
the intervention group.
The preceding results assume mean scores for patients
still active in the study at 24 months are representative
of all patients participating in the study, including those
patients who started but did not complete the study be-
cause of dropout due to death, transfer to another modal-
ity, or transplant. Examination of patient status at end of
study, however, reveals that only 42% of patients com-
pleted the minimum planned follow-up of 24 months
and, hence, had completed the HRQOL evaluation at
that time point, the balance having dropped out because
of death (22.1% control; 21.1% intervention), transplant
(7.6% control; 5.4% intervention), transfer to hemodial-
ysis (9.78% control; 13.4% intervention), loss to follow-
up (9.78% control; 7.77% intervention), or other. Since
patient HRQOL generally declines immediately prior to
an adverse event, such as death or transfer to another
modality, it is important to conduct some sort of sensitiv-
ity analysis to determine if patient dropout is informative
with respect to mean changes in HRQOL. For example,
it is reasonable to assume that patients who drop out be-
fore a scheduled visit have a worse HRQOL than those
who complete their HRQOL questionnaire at the time
of their scheduled visit. If this is true, then unadjusted
comparisons are likely to be biased.
In this study, although the overall rate of dropout is
similar for both groups, there were differences in rea-
sons for dropout by treatment group. In particular, there
was a higher percentage of dropout among patients in
the intervention group compared to the control group for
reasons of discomfort (intervention: 3.7%, control: 0.2%,
P < 0.001); hernia (intervention: 2.6%, control: 0.9%,
P < 0.05); and peritonitis (intervention: 9.7%, control:
5.7%, P < 0.05). Conversely, 24 of 460 (5.2%) control pa-
tients dropped out due to uremia compared to none for
the intervention group (P < 0.001). Given the substan-
tial dropout that occurred over the course of the study
and the close relationship that may exist between quality
of life and adverse events associated with patient with-
drawal, it is very possible that unadjusted mean HRQOL
scores observed over the course of the study unfairly re-
flect a relatively healthier population of patients left be-
hind. Such selection bias caused by patient dropout can
result in HRQOL data that are informatively censored,
which, in turn, can result in biased estimates of mean
HRQOL over time.
Illustrations of the effects of informative censoring
are depicted in Figures 1 to 3, where mean PCS, MCS,
and KDCS scores are plotted against time according to
the different patterns of missing data resulting from pa-
tient dropout (i.e., according to the patient’s last mea-
sured HRQOL). For example, as illustrated in Figure 1,
those patients who drop out before 12 months had a sig-
nificantly different mean PCS profile compared to both
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Fig. 1. Physical component summary scores (PCS) (mean ± 1 SE) by
pattern of patient dropout (or last measured QOL).
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Fig. 2. Mental component summary scores (MCS) (mean ± 1 SE) by
pattern of patient dropout (or last measured QOL).
those who last completed their HRQOL assessment at
12 months (P < 0.001) and to those that last completed
their HRQOL assessment at 24 months (P < 0.001). Like-
wise, patients who completed their 12-month HRQOL
assessment but not their 24-month assessment had lower
mean PCS scores than those who completed their
24-month HRQOL assessment (P = 0.0246). Similar re-
sults are seen with the MCS scores (Fig. 2) and KDCS
scores (Fig. 3).
In order to more accurately estimate and compare
mean HRQOL scores between intervention and control
patients, and to compare mean changes from baseline
between the two groups, we included the four different
patterns of missing data resulting from patient dropout as
covariates within a repeated measures ANCOVA model.
The results show that there is little or no difference in
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Fig. 3. Kidney disease component summary scores (KDCS) (mean ±
1 SE) by pattern of patient dropout (or last measured QOL).
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Fig. 4. Comparison of adjusted physical component summary scores
(PCS) temporal profiles in the control and intervention groups. No
differences between the two groups were observed at any time point.
Mean ± 1 SE.
patient quality of life between patients receiving stan-
dard 4×2 L CAPD versus those receiving a modified
CAPD prescription aimed at achieving a peritoneal cre-
atinine clearance ≥60 L/week/1.73m2. These results are
portrayed graphically in Figures 4 to 6.
The effect of ignoring patient dropout in the analysis is
illustrated in Figure 7, which compares adjusted and un-
adjusted mean physical component summary scores over
the course of the study for both control and intervention
patients. For both groups, the unadjusted (raw) mean PCS
scores tend to be inflated over time because patients who
remain in the study longer tend to be healthier than those
who dropout. When adjusted for the different patterns of
patient dropout, the mean PCS scores are lower than the
raw scores, suggesting that analyses that ignore missing
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Fig. 5. Comparison of adjusted mental component summary scores
(MCS) temporal profiles in the control and intervention groups. No
differences between the two groups were observed at any time point.
Mean ± 1 SE.
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Fig. 6. Comparison of adjusted kidney disease component summary
scores (KDCS) temporal profiles in the control and intervention groups.
No differences between the two groups were observed at any time point.
Mean ± 1 SE.
HRQOL scores due to patient dropout may yield overly
optimistic values. Similar trends are seen with respect to
mean MCS and mean KDCS scores (data not shown).
In the majority of cases, trends over time within both the
control and intervention groups showed a general decline
in HRQOL over a 24-month time frame, although there
were trends for a small increase in HRQOL six months’
post baseline. There were no statistically significant dif-
ferences in mean changes from baseline between control
and intervention patients for either the physical, mental,
or kidney disease component summary scores.
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Fig. 7. Adjusted versus unadjusted physi-
cal component summary scores over time in
the two groups. Use of unadjusted values
would have obscured the temporal decline in
HRQOL in both groups.
Table 3. Effect of baseline age, serum albumin, presence of diabetes, starting GFR, and gender on patient quality of life
Covariate
Instrument Domain Age Albumin Diabetes GFR Female
KD QOL Kidney Disease Component Summary −0.138c 0.922 −5.719c 0.506c 0.154
Symptom problem −0.119 1.508 −7.256c 0.799b −3.017b
Dialysis staff encouragement −0.004 0.391 0.043 0.096 −0.418
Patient satisfaction −0.101b 1.826b −6.366c 0.223 −0.990
Effects of kidney disease −0.109 0.982 −8.343c 1.019c 1.726
Burden of kidney disease −0.249b 0.722 −11.23c 0.574 4.151
Work status −0.496c 3.048 −13.11c 1.739b −1.324
Cognitive function 0.104 −1.242 4.715a −0.641 1.326
Quality of social interaction 0.003 −1.173 3.951a −0.249 −1.429
Sexual function −0.515 2.317 −18.79c 1.620a 4.053
Sleep −0.241c 0.794 −7.804c 1.098b −0.222
Social support 0.038 −0.131 −4.356b −0.078 1.535
SF-36 Mental Component Summary −0.002 1.231 −4.527c 0.462b −1.083
Physical Component Summary −0.135c 1.799b −5.159c 0.585c −1.242
Physical functioning −0.409c 5.737c −18.62c 1.534c −5.442b
Role-physical −0.294a 6.342b −13.86c 1.798b 0.892
Pain −0.248c 2.966a −8.767c 0.947a −5.720c
General health −0.077 2.793a −8.814c 1.177b −1.410
Emotional well-being −0.062 2.921a −9.946c 0.910b −3.776a
Role-emotional −0.156 4.834a −14.74c 1.225a −2.841
Social function −0.093 3.448a −10.52c 1.050b −0.360
Energy/fatigue −0.162a 3.715b −13.11c 1.246b −3.287a
Value is the change in value of the mean QOL score per 1 unit increase in the value of the covariate.
aP < 0.05.
bP < 0.01.
cP < 0.001.
Correlates of baseline HRQOL
In order to investigate what effects gender, age, dia-
betes, prior time on dialysis (months), and baseline val-
ues of GFR (mL/min), serum albumin (g/dL), hematocrit,
and nPNA (g/kg/day) have on patient HRQOL, we fit the
data to a repeated measures ANCOVA model. The re-
sults, summarized in Table 3, indicate that older age, lower
serum albumin, presence of diabetes, lower starting GFR,
and female gender are all significantly associated with de-
creased quality of life. For the most part, hematocrit, prior
months on dialysis, and nPNA levels at baseline were not
predictive of HRQOL, although higher hematocrit levels
were associated with a higher HRQOL in terms of bur-
den of kidney disease (value = 0.484, P < 0.05) and social
support (value = 0.251, P < 0.05), while prior months on
dialysis was associated with higher HRQOL in terms of
work status (value = 0.151, P < 0.01) and role physical
(value = 1.107, P < 0.05). Protein intake as measured via
nPNA was associated with better HRQOL in terms of pa-
tient satisfaction (value = 4.908, P < 0.01), physical func-
tioning (value = 12.638, P < 0.01), and role-emotional
(value = 13.252, P < 0.05).
Predictive value of baseline HRQOL
We compared overall patient survival between in-
tervention and control groups using baseline HRQOL
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Table 4. Associations between baseline characteristics and mortality
rates
Effect RR (95% CI)1 RR (95% CI)2
Treatment (control) 1.10 (0.86,1.40) NS 1.14 (0.89,1.46) NS
Gender (male) 1.21 (0.95, 1.55) NS 1.29 (1.002, 1.65)a
Age (per 10 year ?) 1.14 (1.01, 1.28) 1.15 (1.03, 1.29)a
DM (non-DM) 1.75 (1.31, 2.34)c 1.71 (1.27, 2.30)c
Serum albumin 0.94 (0.92, 0.96)c 0.94 (0.93, 0.96)c
(per 0.1 g/dL ?)
nPNA (per 0.1 g/kg/day ?) 0.92 (0.86, 0.98)b 0.91 (0.86, 0.97)a
PCS (per 5-point scale ?) 1.13 (1.06, 1.21)c
MCS (per 5-point scale ?) 1.07 (1.02, 1.12)b
KDCS (per 5-point scale ?) 1.14 (1.07, 1.23)c
NS, Not Significant, A Cox regression analysis was run comparing treatment
groups adjusted for gender, age, diabetes, and baseline values of albumin, nPNA,
and QOL (as measured by PCS, MCS. and KDCS scores). Adjusted for PCS and
MCS as these two scores are approximately uncorrelated. Adjusted for KDCS
independent of PCS and MCS (with which KDCS is correlated).
aP < 0.05.
bP < 0.01.
cP < 0.001.
measures as covariates. The results, shown in Table 4,
clearly demonstrate the impact low starting HRQOL has
on subsequent patient outcomes. In particular, even af-
ter adjusting for age, diabetes, nPNA, and serum albu-
min, there was a strong and significant association be-
tween baseline physical, mental, and kidney disease com-
ponent summary scores and mortality, as assessed using a
Cox proportional hazards model. Because PCS and MCS
scores are constructed to be approximately uncorrelated,
they were included in one Cox model, while KDCS scores
were included in a second Cox model because of the
high correlation that exists between KDCS scores and
both PCS and MCS scores. Similarly, identical analysis re-
vealed that even after adjusting for age, diabetes, nPNA,
and serum albumin, there was a strong and significant as-
sociation between baseline physical, mental, and kidney
disease component summary scores and hospitalization
rates (Table 5) and hospitalization days (Table 5) (as as-
sessed using Poisson regression). Again, because PCS and
MCS scores are constructed to be approximately uncor-
related, they were included in one model, while KDCS
scores were included in a second model.
The impact of baseline HRQOL parameters on sur-
vival is further illustrated in Figure 8A to C. In this anal-
ysis, the population was divided into subgroups based on
the median for each composite summary score. Patients
with values above the median for PCS (Fig. 8A), MCS
(Fig. 8B), or KDCS (Fig. 8C) had a better survival than
patients with values below the median for these compos-
ite summary scores, irrespective of the study arm (control
vs. intervention) to which they were randomized.
Identical analysis revealed that after adjusting for age,
diabetes, nPNA, and serum albumin, there was no associ-
ation between baseline physical, mental, and kidney dis-
ease component summary scores and technique survival,
as assessed using a Cox proportional hazards model.
Table 5. Associations between baseline characteristics and
hospitalization rates and hospitalization days
Effect RRc (95% CI)a RRc (95% CI)b
Hospitalization rate
Treatment (control) 1.13 (0.95,1.33)NS 1.10 (0.92,1.31)NS
Gender (male) 1.15 (0.97, 1.36) NS 1.19 (0.99, 1.42) NS
Age (per 10 year ↑) 0.92 (0.85, 0.99)d 0.91 (0.85, 0.99)d
DM (non-DM) 1.38 (1.13, 1.70)e 1.47 (1.19, 1.83)f
Serum albumin 0.97 (0.96, 0.98)f 0.97 (0.95, 0.98)f
(per 0.1 g/Dl ↑)
nPNA (per 0.1 g/kg/day ↑) 0.97 (0.93, 1.01) NS 0.97 (0.93, 1.02) NS
PCS (per 5-point scale ↓) 1.07 (1.03, 1.12)e
MCS (per 5-point scale ↓) 1.04 (1.003, 1.08)d
KDCS (per 5-point scale ↓) 1.05 (1.00, 1.10)d
Hospitalization days
Treatment (control) 1.10 (0.89,1.37) NS 1.07 (0.86,1.34) NS
Gender (male) 1.11 (0.89, 1.39) NS 1.15 (0.92, 1.45) NS
Age (per 10 year ↑) 1.00 (0.91, 1.11) NS 1.00 (0.90, 1.10) NS
DM (non-DM) 1.48 (1.14, 1.92)e 1.55 (1.18, 2.04)e
Serum albumin 0.97 (0.95, 0.99)e 0.97 (0.95, 0.99)e
(per 0.1 g/dL ↑)
nPNA (per 0.1 g/kg/day ↑) 0.98 (0.92, 1.03) NS 0.97 (0.92, 1.03) NS
PCS (per 5-point scale ↓) 1.06 (0.99, 1.12) NS
MCS (per 5-point scale ↓) 1.07 (1.03, 1.12)e
KDCS (per 5-point scale ↓) 1.08 (1.02, 1.15)d
NS, not significant. A Poisson regression analysis was run comparing treatment
groups adjusted for gender, age, diabetes, and baseline values of albumin, nPNA,
and QOL (as measured by PCS, MCS, and KDCS scores).
aAdjusted for PCS and MCS as these two scores are approximately
uncorrelated.
bAdjusted for KDCS independent of PCS and MCS (with which KDCS is
correlated).
cRate ratio.
dP < 0.05.
eP < 0.01.
fP < 0.001.
DISCUSSION
The findings of this study can be summarized as fol-
lows. Enhancement of peritoneal small solutes clearance
has no beneficial effect on the evolution of quality of life
in CAPD patients. Measures of quality of life have a sig-
nificant predictive value for CAPD patients’ survival, oc-
currence of hospitalizations, and their duration. HRQOL
measures do not appear to influence technique survival
on CAPD.
Because of the importance of the issue of dialysis dose
in current nephrologic discourse [40, 44], we undertook
a very detailed and rigorous evaluation of the effects of
small solutes clearances on parameters of HRQOL. Both
unadjusted and adjusted analysis were carried out com-
paring mean scores of KDQOL domains and summary
scores between control and intervention groups at each
follow-up of 6, 12, and 24 months. HRQOL changes from
baseline to 6, 12, and 24 months of follow-up were also
compared between the two groups.
In the unadjusted analysis, no long-term (12 and
24 months of follow-up) HRQOL difference was found
between the two groups. At six months (short-term), a
significant difference favoring the intervention group was
observed in four of the KDQOL domains (burden of kid-
ney disease, effects of kidney disease, sexual function, and
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Fig. 8. (A) Patient survival by value of physical composite summary
score (PCS) and study arm. Patients with PCS values below the mean
(<37.5) had a worse survival than patients above the mean irrespective
of the study arm they were randomized to. There were no differences
between control and intervention in either subset of PCS. (B) Patient
survival by value of mental composite summary score (MCS) and study
arm. Patients with MCS values below the mean (<50) had a worse sur-
vival than patients above the mean irrespective of the study arm they
were randomized to. There were no differences between control and
intervention in either subset of MCS. (C) Patient survival by value of
kidney disease composite summary score (KDCS) and study arm. Pa-
tients with KDCS values below the mean (<53) had a worse survival
than patients above the mean irrespective of the study arm they were
randomized to. There were no differences between control and inter-
vention in either subset of KDCS.
symptom problem), while patients in the control group
had a significantly higher HRQOL score in two of the
KDQOL domains (cognitive function and quality of so-
cial interaction). There was also evidence of small im-
provement in the physical component summary score for
the intervention group at six months. After adjusting for
different patterns of patient dropout, however, the num-
ber of HRQOL domains showing a benefit at six months
was reduced from six to four with three (effects of kidney
disease, sexual function, and symptom problem) favoring
the intervention group and one (quality of social interac-
tion) favoring the control group, and no differences in
the composite summary scores were found between the
control and intervention groups at any time point. We
have illustrated the potential bias introduced by infor-
mative censoring at length in the Results section of this
report, and would stress the importance of giving defini-
tive weight to the adjusted analysis in interpreting the
findings of our study. Our results confirm the findings
of previous smaller and uncontrolled studies in PD pa-
tients in whom dialysis dose has not been found to affect
HRQOL measures [25, 34, 39].
Determinants of HRQOL in patients on peritoneal
dialysis (PD) have been previously studied in small pa-
tient groups. The present study is the largest cross-
sectional and longitudinal interventional study of quality
of life in patients on peritoneal dialysis. Our findings con-
firm several of the observations done in the smaller stud-
ies regarding associations between patient characteristics
and HRQOL measures such as age, gender [25], comor-
bidity [25, 34, 35], nutritional status [25, 35], and resid-
ual renal function [34, 35]. Many of these parameters are
amenable to therapeutic interventions. While our study
did not involve planned changes in these parameters, it
is not unreasonable to suggest that measures to improve
nutritional status, to protect residual renal function, and
control the effects of comorbidities before and after the
initiation of dialysis would have a salutary effect on pa-
tient HRQOL. Additionally, women with ESRD may be
more vulnerable to have lower HRQOL and, hence, may
need to be targeted for special care.
It is of interest to compare the baseline HRQOL mea-
sures in this large population of patients on PD and the
findings in dialysis patients reported by others. Figures 9A
to C compare corresponding HRQOL summary scores
and specific domains in ADEMEX and the large HD pop-
ulation studied in the DOPPS initiative [23]. The figures
illustrate that in the majority of measures, the scores in
the ADEMEX population equal or exceed those in HD
patients in DOPPS.
Baseline values of HRQOL in this study were highly
predictive of subsequent patient survival, with lower
HRQOL associated with higher mortality. This observa-
tion is similar to findings in both patients on HD and
patients on PD. In patients on HD, measures of HRQOL
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Fig. 9. (A) Composite summary scores in patients on peritoneal dialy-
sis (PD) (ADEMEX) and patients on hemodialysis (DOPPS), the latter
data from ref [23]. (B) SF-36 domain scores in patients on PD (ADE-
MEX) and patients on hemodialysis (DOPPS), the latter data from ref
[23]. (C) Disease-specific domain scores in patients on PD (ADEMEX)
and patients on hemodialysis (DOPPS), the latter data from ref [23].
have been found to be strong independent predictors of
hospitalization and increased risk of death [16, 23, 24,
37, 56–58]. Mapes et al [23], reporting on the largest
cross-sectional study in HD, showed highly significant
associations between lower HRQOL scores and higher
risk of death and hospitalization among hemodialysis
patients. These inverse associations between HRQOL
and outcomes were observed for all three components
of the KDQOL-SF (i.e., MCS, PCS, and KDCS) [23].
These associations remained statistically significant after
adjustment for several risk factors of death or hospitaliza-
tion, including serum albumin concentration, sociodemo-
graphic characteristics, years on dialysis, type of vascular
access, several comorbidities, and treatment factors [23].
Previous studies in patients on PD have also shown
measures of HRQOL to be strong independent predic-
tors of increased risk of death and hospitalizations [25,
37]. Merkus et al [37] studied prospectively a cohort of
189 patients, and found that baseline presence of comor-
bidity, serum albumin level of 30 g/L or less, physical or
mental quality-of-life score 2 or more standard devia-
tions less than the general population mean score, and,
to a lesser extent, residual glomerular filtration rate of
2.5 mL/min/1.73m2 or less were independently associated
with a greater risk for poor outcome. Bakewell et al [25]
found in 88 patients in the UK a strong correlation be-
tween poor QOL and increased rate of hospitalization.
In the present study, similar to the findings of Mapes
et al [23] in patients on HD, we found associations be-
tween all three composite scores of HRQOL (PCS, MCS,
KDCS) and the relative risk of death. These associations
remained statistically significant even after adjustments
for age, presence of diabetes, baseline serum albumin,
and baseline nPNA (Table 5), each of which was associ-
ated independently with risk of death. We also observed
in a manner analogous to the findings of DeOreo [56] in
patients on HD, that PD patients with composite scores
(PCS, MCS, or KDCS) below the median had a worse
survival than patients with composite scores above the
median (Fig. 8A-C), independent of the dose of dialysis.
Similar to the findings of Mapes et al [23] in HD also,
we observed strong associations between all three com-
posite scores of HRQOL (PCS, MCS, KDCS) and the
rate of hospitalization and the number of hospitaliza-
tion days. These associations remained statistically signifi-
cant even after adjustments for age, presence of diabetes,
baseline serum albumin, and baseline nPNA (Tables 4
and 5), each of which was associated independently with
hospitalization.
In the primary outcome report from the ADEMEX
study [45], we showed that deliberate increase in peri-
toneal small solute clearance had no effect on patient
survival. We stressed in that report that the failure to
show a beneficial effect on survival in large patient co-
horts does not imply that the welfare of individual pa-
tients may not be better served by enhancing the dose
of dialysis [45]. We have also stressed elsewhere [44] that
measures of small solute clearances alone can be uninfor-
mative, and that they need to be considered in the context
of the overall care of the patient, in general, and the needs
of metabolic correction in particular [44]. These earlier
remarks were directed at avoiding therapeutic nihilism
that may arise from a misinterpretation of our findings.
These deliberations are crucial to reinvoke in the present
context because of our findings of a neutral effect of en-
hanced small solute clearance on HRQOL. Our present
report has identified areas of vulnerability in patients’
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profile that may help guide future care. Women and pa-
tients with suboptimal nutritional status may need to be
targeted for special care. Further, measures to protect
residual renal and comorbidities effects may be trans-
lated into improved HRQOL.
CONCLUSION
ADEMEX is the first large randomized, prospective,
controlled clinical trial that examined the correlates of
HRQOL in patients on CAPD and the effects of peri-
toneal small solute clearance on patient HRQOL. Based
on this randomized controlled trial, there is no evidence
of a long-term benefit in HRQOL by increasing peri-
toneal small-solute clearances when aggregated physical,
mental, and kidney disease component summary scores
were used in combination with analyses that adjust for
patient dropout. These results reinforce the need to ad-
just for possible biased censoring due to patient dropout
when estimating and comparing QOL over time. Mea-
sures of HRQOL have a significant predictive value for
CAPD patients’ survival, occurrence of hospitalizations,
and their duration.
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